Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?

por Jang, Albert, Adler, David M., Rauterkus, Grant P., Bilen, Mehmet A., Barata, Pedro C.
Publicado 2021

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)

por Bilen, Mehmet A, Robinson, Scott B, Schroeder, Amy, Peng, Jing, Kim, Ruth, Liu, Frank X, Bhanegaonkar, Abhijeet
Publicado 2023

Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma

por Zakka, Katerina, Zakka, Patrick, Davarpanah, Amir, Koshkelashvili, Nikoloz, Bilen, Mehmet A., Owonikoko, Taofeek, El-Rayes, Bassel, Akce, Mehmet
Publicado 2020

Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus

por Master, Viraj A., Schmeusser, Benjamin N., Osunkoya, Adeboye O., Palacios, Arnold R., Midenberg, Eric, Yantorni, Lauren, Ogan, Kenneth, Bilen, Mehmet A.
Publicado 2022

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report

por Bilen, Mehmet A., Jiang, James F., Jansen, Caroline S., Brown, Jacqueline T., Harik, Lara R., Sekhar, Aarti, Kissick, Haydn, Maithel, Shishir K., Kucuk, Omer, Carthon, Bradley, Master, Viraj A.
Publicado 2021

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

por Barata, Pedro, Hatton, Whitley, Desai, Arpita, Koshkin, Vadim, Jaeger, Ellen, Manogue, Charlotte, Cotogno, Patrick, Light, Malcolm, Lewis, Brian, Layton, Jodi, Sartor, Oliver, Basu, Arnab, Kilari, Deepak, Emamekhoo, Hamid, Bilen, Mehmet A.
Publicado 2020

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with...

por Jonasch, Eric, Hauke, Ralph, Falchook, Gerald, Logan, Theodore, Gordon, Michael, Hall, Evan, Schuch, Brian, Bilen, Mehmet A, Naqash, Abdul, Zakaharia, Yousef, Ryan, Christopher W, Lally, Satwant, Xiao, Jim, Zimmerman, Zachary, Srinivasan, Ramaprasad, Choueiri, Toni K
Publicado 2023

A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma

por Sekar, Rishi R., Patil, Dattatraya, Baum, Yoram, Pearl, Jeffrey, Bausum, Anna, Bilen, Mehmet A., Kucuk, Omer, Harris, Wayne B., Carthon, Bradley C., Alemozaffar, Mehrdad, Filson, Christopher P., Pattaras, John G., Nieh, Peter T., Ogan, Kenneth, Master, Viraj A.
Publicado 2017

Clinic friendly estimation of muscle composition: Preoperative linear segmentation shows overall survival correlated with muscle mass in patients with nonmetastatic renal cell carc...

por Schmeusser, Benjamin N., Midenberg, Eric, Palacios, Arnold R., Vettikattu, Nikhil, Patil, Dattatraya H., Medline, Alexandra, Higgins, Michelle, Armas-Phan, Manuel, Nabavizadeh, Reza, Joshi, Shreyas S., Narayan, Vikram M., Psutka, Sarah P., Ogan, Kenneth, Bilen, Mehmet A., Master, Viraj A.
Publicado 2022

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors

por Shabto, Julie M., Martini, Dylan J., Liu, Yuan, Ravindranathan, Deepak, Brown, Jacqueline, Hitron, Emilie E., Russler, Greta A., Caulfield, Sarah, Kissick, Haydn, Alemozaffar, Mehrdad, Ogan, Kenneth, Harris, Wayne B., Master, Viraj A., Kucuk, Omer, Carthon, Bradley C., Bilen, Mehmet A.
Publicado 2020

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer

por Freeman, Meredith N, Jang, Albert, Zhu, Jason, Sanati, Farhad, Nandagopal, Lakshminarayanan, Ravindranathan, Deepak, Desai, Arpita, Phone, Audrey, Nussenzveig, Roberto, Jaeger, Ellen, Caputo, Sydney A, Koshkin, Vadim S, Swami, Umang, Basu, Arnab, Bilen, Mehmet A, Agarwal, Neeraj, Sartor, Oliver, Burgess, Earle F, Barata, Pedro C
Publicado 2022

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

por Tannir, Nizar M, Cho, Daniel C, Diab, Adi, Sznol, Mario, Bilen, Mehmet A, Balar, Arjun V, Grignani, Giovanni, Puente, Erika, Tang, Lily, Chien, David, Hoch, Ute, Choudhury, Arkopal, Yu, Danni, Currie, Sue L, Tagliaferri, Mary A, Zalevsky, Jonathan, Siefker-Radtke, Arlene O, Hurwitz, Michael E
Publicado 2022

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

por Abou Alaiwi, Sarah, Xie, Wanling, Nassar, Amin H, Dudani, Shaan, Martini, Dylan, Bakouny, Ziad, Steinharter, John A, Nuzzo, Pier Vitale, Flippot, Ronan, Martinez-Chanza, Nieves, Wei, Xiao, McGregor, Bradley A, Kaymakcalan, Marina D, Heng, Daniel Y C, Bilen, Mehmet A, Choueiri, Toni K, Harshman, Lauren C
Publicado 2020

Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race

por Zimmerman, Raquel, Bilen, Mehmet A, Heath, Elisabeth I, Nandagopal, Lakshminarayanan, Swami, Umang, Kessel, Adam, Jaeger, Ellen, Wesolowski, Sergiusz, Hernanadez, Edgar J, Chipman, Jonathan, Mack, Alleda, Ravindranathan, Deepak, Maughan, Benjamin L, Nussenzveig, Roberto, Yandell, Mark, Kohli, Manish, Lilly, Michael B, Sartor, A Oliver, Agarwal, Neeraj, Barata, Pedro C
Publicado 2022

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase...

por Bilen, Mehmet A., Rini, Brian I., Voss, Martin H., Larkin, James, Haanen, John B.A.G., Albiges, Laurence, Pagliaro, Lance C., Voog, Eric G., Lam, Elaine T., Kislov, Nikolay, McGregor, Bradley A., Lalani, Aly-Khan A., Huang, Bo, di Pietro, Alessandra, Krulewicz, Stan, Robbins, Paul B., Choueiri, Toni K.
Publicado 2022

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

por Harvey, R. Donald, Carthon, Bradley C., Lewis, Colleen, Hossain, Mohammad S., Zhang, Chao, Chen, Zhengjia, Harris, Wayne B., Alese, Olatunji B., Shaib, Walid, Bilen, Mehmet A., Lawson, David H., Wu, Christina, Steuer, Conor E., El-Rayes, Bassel F., Khuri, Fadlo R., Lonial, Sagar, Waller, Edmund K., Ramalingam, Suresh S., Owonikoko, Taofeek K.
Publicado 2020

High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells

por Boya, Mert, Ozkaya-Ahmadov, Tevhide, Swain, Brandi E., Chu, Chia-Heng, Asmare, Norh, Civelekoglu, Ozgun, Liu, Ruxiu, Lee, Dohwan, Tobia, Sherry, Biliya, Shweta, McDonald, L. DeEtte, Nazha, Bassel, Kucuk, Omer, Sanda, Martin G., Benigno, Benedict B., Moreno, Carlos S., Bilen, Mehmet A., McDonald, John F., Sarioglu, A. Fatih
Publicado 2022

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

por Carlisle, Jennifer Wilkinson, Jansen, Caroline S, Cardenas, Maria Andrea, Sobierajska, Ewelina, Reyes, Adriana Moon, Greenwald, Rachel, Del Balzo, Luke, Prokhnevska, Nataliya, Kucuk, Omer, Carthon, Bradley C, Mullane, Patrick Connor, Osunkoya, Adeboye, Baumgarten, Deborah, Hosseinzadeh, Fares, Wilkinson, Scott, Lake, Ross, Sowalsky, Adam G, Liu, Yuan, Master, Viraj A, Bilen, Mehmet A, Kissick, Haydn
Publicado 2022

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

por Atkins, Michael B., Jegede, Opeyemi A., Haas, Naomi B., McDermott, David F., Bilen, Mehmet A., Stein, Mark, Sosman, Jeffrey A., Alter, Robert, Plimack, Elizabeth R., Ornstein, Moshe, Hurwitz, Michael, Peace, David J., Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J., Braun, David, Einstein, David, Catalano, Paul J., Hammers, Hans
Publicado 2022

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

por Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, McDermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey A, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J, Braun, David, Einstein, David, Catalano, Paul J, Hammers, Hans
Publicado 2023